Oncolytics Biotech's All Planned Facilities For Part A Of REO 033 Trial Activated, Multiple Participants Admitted

Oncolytics Biotech Inc. (NASDAQ: ONCY) has activated nearly all planned clinical sites for Part A of its REO 033 trial, which is evaluating the immunotherapy pelareorep in patients with second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer. Multiple patients have already been enrolled in the study. The company is now concentrating on accelerating patient enrollment and generating randomized clinical data to assess the efficacy of pelareorep alongside the current standard-of-care treatment.